Health
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany, May 21, 2026--Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
About this update from Merck Kgaa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bfb98c4e6bdefbd72921ff8df3f51a30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aHqSNEcsFmVf6YIEvbGEsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/bfb98c4e6bdefbd72921ff8df3f51a30","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/4E50yVV1p.fZIGr5lzrArA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/bfb98c4e6bdefbd72921ff8df3f51a30","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uCk84HCDaHh1uwDztP4c3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/bfb98c4e6bdefbd72921ff8df3f51a30","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC)","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection","length":103,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide","length":146,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":392,"olType":false},{"type":"text","content":"Not intended for UK-based media","length":31,"tagName":"p"},{"type":"text","content":"DARMSTADT, Germany, May 21, 2026--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem-TcT), a potential first-in-class investigational anti-CEACAM5 antibody-drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC).","length":438,"tagName":"p"},{"type":"text","content":""Leveraging our novel payload-linker technology, Precem-TcT is the first CEACAM5-targeted ADC in clinical studies with...